Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...

Correspondence to Dr Zhiqi Zhang, Department of Joint Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China; zhzhiqi{at}mail.sysu.edu.cn; Dr Weiming Liao; ...

Study of the genetics of rheumatoid arthritis (RA) began about four decades ago with the discovery of HLA-DRB1. Since the beginning of this century, a number of non-HLA risk loci have been identified ...

15 Amsterdam Rheumatology and Immunology Centre, Reade, Amsterdam, The Netherlands Objectives We sought to investigate whether genetic effects on response to TNF inhibitors (TNFi) in rheumatoid ...

Correspondence to Dr Zachary Scott Wallace, Division of Rheumatology, Allergy, and Immunology and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General ...

3 Competence Centre for Clinical Research, Skane University Hospital, Lund, Sweden 4 Department of Nephrology and Transplantation, Skane University Hospital Malmö, Lund University, Sweden Introduction ...

Objectives Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in ...

Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada Radiology Department, Department of Medicine, Vancouver General Hospital, University of British Columbia, ...

Background Increased levels of the tumour necrosis factor (TNF) -ligand APRIL (A Proliferation Inducing Ligand) were found in synovial fluid and serum of patients with inflammatory arthritis pointing ...

Background: We have previously found promise in NMR as a tool to distinguish sera of active from inactive inflammatory myositis (IIM)1. To understand the changes previously found in sera and urine we ...

Correspondence to Simon Rothwell, Centre for Genetics and Genomics, Arthritis Research UK, University of Manchester, Manchester M13 9PL, UK; s.rothwell{at}manchester.ac.uk Objectives Idiopathic ...

Background: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout. In Phase 1 healthy subject studies, ...